Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada

Sonya Cressman, Stephen Lam, Martin C. Tammemagi, William K. Evans, Natasha B. Leighl, Dean A. Regier, Corneliu Bolbocean, Frances A. Shepherd, Ming Sound Tsao, Daria Manos, Geoffrey Liu, Sukhinder Atkar-Khattra, Ian Cromwell, Michael R. Johnston, John R. Mayo, Annette McWilliams, Christian Couture, John C. English, John Goffin, David M. HwangSerge Puksa, Heidi Roberts, Alain Tremblay, Paul MacEachern, Paul Burrowes, Rick Bhatia, Richard J. Finley, Glenwood D. Goss, Garth Nicholas, Jean M. Seely, Harmanjatinder S. Sekhon, John Yee Frcsc, Kayvan Amjadi, Jean Claude Cutz, Diana N. Ionescu, Kazuhiro Yasufuku, Simon Martel, Kamyar Soghrati, Don D. Sin, Wan C. Tan, Stefan Urbanski, Zhaolin Xu, Stuart J. Peacock

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

43 Citas (Scopus)

Resumen

Background: It is estimated that millions of North Americans would qualify for lung cancer screening and that billions of dollars of national health expenditures would be required to support population-based computed tomography lung cancer screening programs. The decision to implement such programs should be informed by data on resource utilization and costs. Methods: Resource utilization data were collected prospectively from 2059 participants in the Pan-Canadian Early Detection of Lung Cancer Study using low-dose computed tomography (LDCT). Participants who had 2% or greater lung cancer risk over 3 years using a risk prediction tool were recruited from seven major cities across Canada. A cost analysis was conducted from the Canadian public payer's perspective for resources that were used for the screening and treatment of lung cancer in the initial years of the study. Results: The average per-person cost for screening individuals with LDCT was $453 (95% confidence interval [CI], $400-$505) for the initial 18-months of screening following a baseline scan. The screening costs were highly dependent on the detected lung nodule size, presence of cancer, screening intervention, and the screening center. The mean per-person cost of treating lung cancer with curative surgery was $33,344 (95% CI, $31,553-$34,935) over 2 years. This was lower than the cost of treating advanced-stage lung cancer with chemotherapy, radiotherapy, or supportive care alone, ($47,792; 95% CI, $43,254-$52,200; p = 0.061). Conclusion: In the Pan-Canadian study, the average cost to screen individuals with a high risk for developing lung cancer using LDCT and the average initial cost of curative intent treatment were lower than the average per-person cost of treating advanced stage lung cancer which infrequently results in a cure.

Idioma originalEnglish
Páginas (desde-hasta)1449-1458
Número de páginas10
PublicaciónJournal of Thoracic Oncology
Volumen9
N.º10
DOI
EstadoPublished - oct. 1 2014
Publicado de forma externa

Nota bibliográfica

Funding Information:
This project was funded in part by the Terry Fox Research Institute, the Canadian Partnership Against Cancer, with cofunding by the Princess Margaret Cancer Foundation Lusi Wong Fund (Toronto site). The Canadian Centre for Applied Research in Cancer Control (ARCC) is funded by the Canadian Cancer Society Research Institute.

Publisher Copyright:
Copyright © 2014 by the International Association for the Study of Lung Cancer.

ASJC Scopus Subject Areas

  • Oncology
  • Pulmonary and Respiratory Medicine

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Huella

Profundice en los temas de investigación de 'Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada'. En conjunto forman una huella única.

Citar esto